Table 1.
Screening demographics of patients with stable chronic bronchitis.
| Age * | 59.1 ± 10.6 |
| Race Caucasian n (%) | 59 (87%) |
| Sex Male n (%) | 42 (61%) |
| Current Smoker n (%) | 28 (41%) |
| Pack Years+ | 41.9 ± 25.4 |
| FVC (percent predicted)# | 3.48 ± 0.96 (84.1%) |
| FEV1 (percent predicted)# | 2.01± 0.86 (63.4%) |
| FEV1/FVC# | 56.7 ± 15.5 |
| GOLD Stage (no. in 0,1,2,3)ǂ | 15,3,28,22) |
| Reversibility§ | 11.8 ± 13.2 |
| Inhaled Corticosteroid Use- Yes n¶ | 30 (44%) 69 |
*
Values are means ± SD
+
Pack Years = number of packs of cigarettes per day multiplied by the number of years smoked
#
Spirometry was measured post-bronchodilator, % predicted values utilized reference values from Hankinson
ǂ
GOLD Stage: GOLD 0= FEV1/FVC >0.7 and FEV1 % Predicted is >80%; GOLD 1= FEV1/FVC <0.7 and FEV1 % predicted >80%; Gold 2= FEV1/FVC <0.7 and FEV1 % predicted=50–79%; GOLD 3= FEV1/FVC <0.7 and FEV1 % predicted= 30–49%.
§
Reversibility calculated as ((post BD FEV1 - Pre BD FEV1)/Pre BD FEV1) x 100
¶
No duplicate subjects. Screening values for subjects participating in multiple aims were only utilized once.